Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.06)
# 3,019
Out of 4,970 analysts
112
Total ratings
38%
Success rate
-4.71%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLNN Clene | Maintains: Buy | $83 → $48 | $5.59 | +758.68% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $4.71 | +218.47% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $10.62 | +154.24% | 6 | Jul 29, 2025 | |
| ATAI Atai Life Sciences | Maintains: Buy | $12 → $11 | $4.52 | +143.36% | 3 | Jul 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $73 → $70 | $6.01 | +1,064.73% | 8 | Jul 8, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $2.28 | +645.61% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $136.11 | +17.55% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $141.62 | +55.35% | 21 | May 2, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $8.92 | +180.27% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.68 | +226.09% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $3.62 | +2,109.94% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $14.02 | +99.71% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $9.06 | +54.53% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $19.77 | +1.16% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $25.72 | +28.30% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $16.21 | +825.35% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $18.76 | - | 2 | Jan 31, 2017 |
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $5.59
Upside: +758.68%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $4.71
Upside: +218.47%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $10.62
Upside: +154.24%
Atai Life Sciences
Jul 28, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $4.52
Upside: +143.36%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $6.01
Upside: +1,064.73%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $2.28
Upside: +645.61%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $136.11
Upside: +17.55%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $141.62
Upside: +55.35%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $8.92
Upside: +180.27%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.68
Upside: +226.09%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $3.62
Upside: +2,109.94%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $14.02
Upside: +99.71%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $9.06
Upside: +54.53%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $19.77
Upside: +1.16%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $25.72
Upside: +28.30%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $16.21
Upside: +825.35%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $18.76
Upside: -